Breaking News Instant updates and real-time market news.

WSO

Watsco

$142.93

-0.145 (-0.10%)

, LII

Lennox

$223.87

-1.045 (-0.46%)

04:55
01/15/19
01/15
04:55
01/15/19
04:55

Jefferies to hold company meetings

Jefferies Hosted Meetings at AHR Expo 2019 will be held in Atlanta, GA on January 14-15.

WSO

Watsco

$142.93

-0.145 (-0.10%)

LII

Lennox

$223.87

-1.045 (-0.46%)

JCI

Johnson Controls

$32.37

0.19 (0.59%)

PH

Parker-Hannifin

$156.20

-1.73 (-1.10%)

SPXC

SPX Corporation

$29.03

-0.22 (-0.75%)

WTS

Watts Water

$70.10

-0.52 (-0.74%)

  • 15

    Jan

  • 15

    Jan

  • 01

    Feb

  • 28

    Feb

  • 11

    Mar

WSO Watsco
$142.93

-0.145 (-0.10%)

01/02/19
SPHN
01/02/19
NO CHANGE
SPHN
CBS, Global Payments, Union Pacific among Stephens' best ideas for 2019
Stephens released its Best Ideas list for 2019, noting that over the last 13 years its Best Ideas list has outperformed the Russell 2000 by an average of 300 bps. Of note, six of the firm's 30 analysts listed "cash" as their best idea for this year. Among the rest, the picks included: Landstar System (LSTR), Enova (ENVA), RealPage (RP), FMC Corporation (FMC), Avanos (AVNS), Knight-Swift (KNX), CBS (CBS), Vulcan Materials (VMC), Encompass Health (EHC), Watsco (WSO), Global Payments (GPN), O'Reilly Automotive (ORLY), NeoGenomics (NEO), Continental Resources (CLR), Union Pacific (UNP), Ametek (AME), Wintrust Financial (WTFC), Helmerich & Payne (HP), Penske Automotive (PAG), Signature Bank (SBNY), Noble Energy (NBL), Origin Bancorp (OBNK), GrubHub (GRUB) and CenterState Bank (CSFL).
12/18/18
MSCO
12/18/18
INITIATION
Target $144
MSCO
Equal Weight
Watsco initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Joshua Pokrzywinski initiated Watsco with an Equal Weight rating and $144 price target, stating that while its growth over the next few years will likely be smoother than some of the OEMs, he still doesn't expect growth to "be that spectacular." Watsco's growth trajectory is limited despite substantial investments in technology, added the analyst.
10/09/18
BUCK
10/09/18
INITIATION
Target $187
BUCK
Neutral
Watsco initiated with a Neutral at Buckingham
Buckingham initiated Wastco with a Neutral and $187 price target.
10/12/18
JEFF
10/12/18
INITIATION
Target $160
JEFF
Hold
Watsco initiated with a Hold at Jefferies
Jefferies analyst Stephen Volkmann started Watsco with a Hold rating and $160 price target. The analyst views the valuation as fair at current share levels.
LII Lennox
$223.87

-1.045 (-0.46%)

12/13/18
WBLR
12/13/18
NO CHANGE
WBLR
Outperform
Lennox called a top growth story for 2019 at William Blair
William Blair analyst Ryan Merkel calls Lennox International one of his firm's best growth stories for 2019. He views the company's analyst day as positive and keeps an Outperform rating on the name. The duration of Lennox's "high growth" is underappreciated by the Street and as the only HVAC pure-play, the stock deserves its premium valuation, Merkel tells investors in a research note. He keeps an Outperform rating on the name.
12/10/18
BUCK
12/10/18
INITIATION
BUCK
Neutral
Lennox initiated with a Neutral at Buckingham
Buckingham analyst Robert Barry initiated Lennox with a Neutral rating and $219 price target. The analyst said that valuation looks fair outside heightened chatter of M&A, where he feels some deal scenarios are "logical, but quite speculative."
11/19/18
SPHN
11/19/18
INITIATION
Target $229
SPHN
Equal Weight
Lennox initiated with an Equal Weight at Stephens
Stephens analyst Rob McCarthy initiated Lennox with an Equal Weight rating and a price target of $229, saying the company's significant leverage to the North America HVAC market is "currently positive" but may become a headwind on "potentially slowing U.S. residential construction trends. The analyst states that Lennox's "solid premium product portfolio" and "seasoned management" are among its key strengths, but also believes that its shares are "close to fair value given substantial discounting of residential recovery".
10/23/18
FBCO
10/23/18
NO CHANGE
Target $224
FBCO
Outperform
Lennox price target lowered to $224 from $229 at Credit Suisse
Credit Suisse analyst John Walsh lowered his price target for Lennox to $224 from $229 after a Q3 earnings miss driven by higher than expected tornado damages. The analyst notes that this is largely a timing issue as the company expects to fully recover the updated $1.25 of 2018 operational "core" lost profit and an additional 70c of lost earnings for 2019, next year. Walsh reiterates an Outperform rating on the shares.
JCI Johnson Controls
$32.37

0.19 (0.59%)

10/12/18
FBCO
10/12/18
INITIATION
Target $37
FBCO
Neutral
Johnson Controls initiated with a Neutral at Credit Suisse
Credit Suisse analyst John Walsh initiated Johnson Controls with a Neutral rating and $37 price target, telling investors in a research note that Johnson once again finds itself between a rock and a hard place. He believes the current strategic review of Power Solutions will end with a sale or spin, sees Tyco synergies being realized and sees improvement in free cash flow metrics.
11/14/18
OPCO
11/14/18
NO CHANGE
Target $39
OPCO
Outperform
Johnson Controls price target lowered to $39 from $44 at Oppenheimer
Oppenheimer analyst Noah Kaye lowered his price target for Johnson Controls (JCI) to $39 from $44 after the company announced an agreement to sell Power Solutions to Brookfield Business Partners (BBU), concluding the strategic review begun in March. The analyst believes the transaction multiple was reasonable, projected tax leakage was better than he had feared, and management was constructive on deploying sale proceeds for acquisitions. However, without accretive deal-making, the Power sale will be materially dilutive to Johnson Controls' earnings/free cash flow, even with buybacks and corporate savings, he contends. Kaye reiterates an Outperform rating on the shares.
10/12/18
FBCO
10/12/18
INITIATION
FBCO
Outperform
EE, MI Sector initiated with Opportunistic View at Credit Suisse
Credit Suisse analyst John Walsh initiated the U.S. Electrical Equipment and Multi-Industry Sector with an Opportunistic View, telling investors in a research note that he believes at this point in the cycle stock appreciation will be driven by earnings growth and capital allocation. He is most positive on energy-related and non-residential end markets while cautious on Fossil Power markets. Specifically, Walsh initiated Allegion (ALLE), Eaton (ETN), Ingersoll-Rand (IR), Lennox (LII), 3M (MMM) and Xylem (XYL) with Outperform ratings, Acuity Brands (AYI), Emerson (EMR), Flowserve (FLS), Fortiv (FTV), GE (GE), Honeywell (HON) and Johnson Controls (JCI) with Neutral ratings and Rockwell Automation (ROK) with an Underperform rating.
11/16/18
FBCO
11/16/18
INITIATION
Target $54
FBCO
Outperform
Brookfield Business Partners reinstated with an Outperform at Credit Suisse
Credit Suisse analyst Andrew Kuske reinstated coverage of Brookfield Business Partners (BBU) with an Outperform rating and a $54 target price following a brief period of restriction associated with the $13.2B purchase of the Johnson Controls (JCI) Power Solutions Business unit. Given Brookfield's deployment of excess liquidity, Kuske tells investors in a research note that he views the transaction as being a positive for the stock and the deployment momentum that is also supported by strong private client fund raising.
PH Parker-Hannifin
$156.20

-1.73 (-1.10%)

10/15/18
COWN
10/15/18
DOWNGRADE
Target $150
COWN
Underperform
Parker-Hannifin downgraded to Underperform at Cowen
As reported previously, Cowen analyst Joseph Giordano downgraded Parker-Hannifin to Underperform from Market Perform. The analyst cited heightened geopolitical risks, evidence of moderating trends, and key macro indicators with seemingly little room to the upside, and waning estimate momentum. Giordano lowered his price target to $150 from $165 on Parker-Hannifin shares.
10/15/18
10/15/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Parker-Hannifin (PH) and Rockwell Automation (ROK) were downgraded to Underperform from Market Perform at Cowen. 2. Nutrisystem (NTRI) downgraded to Underperform from Neutral at DA Davidson with analyst Linda Bolton Weiser saying she is less confident in the company being able to achieve the over 30% growth in Q4 EBITDA implied by its guidance and believes that the management could cut its outlook, citing "anecdotal evidence" that "steep" price discounting of as high as 29% may be continuing for Nutrisystem's reactivation customers. 3. KLA-Tencor (KLAC) downgraded to In Line from Outperform at Evercore ISI with analyst CJ Muse saying his recent data suggest that WFE orders are tracking to fall about 10% to $45B in FY19, but the decline could be as high as 20% if memory spending does not recover from the DRAM inventory glut-driven slump. 4. Delphi Technologies (DLPH) downgraded to Equal Weight at Morgan Stanley with analyst Armintas Sinkevicius citing the "surprise" CEO transition, stating that the reasons for the change at the top are not clear. 5. Monster Beverage (MNST) downgraded to In Line from Outperform at Evercore ISI with analyst Robert Ottenstein saying he sees fitness/sports energy drinks being poised to take share from traditional energy drinks. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/18
WELS
11/02/18
UPGRADE
Target $193
WELS
Outperform
Parker-Hannifin upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Andrew Casey upgraded Parker-Hannifin to Outperform with an unchanged price target of $193. The recent selloff has created an opportunity "to get back on board the PH stock train," Casey tells investors in a research note. Beyond Parker-Hannifin's short-term earnings beat that was fueled by higher Aerospace segment margins, the analyst sees catalysts for further upside in the shares "despite persistent macro concerns about slowing growth." He expects North American and Aerospace demand continue to grow and points out the company is exiting a period of muted margin performance.
11/02/18
11/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Emergent BioSolutions (EBS) upgraded to Buy from Neutral at Goldman Sachs with analyst Dana Flanders saying he sees an "underappreciated opportunity" for Emergent to expand into other verticals, highlighted by Narcan nasal spray. 2. Michael Kors (KORS) upgraded to Buy from Neutral at UBS and to Overweight from Neutral at Piper Jaffray. 3. Parker-Hannifin (PH) upgraded to Outperform from Market Perform at Wells Fargo with analyst Andrew Casey sayoing the recent selloff has created an opportunity "to get back on board the PH stock train." 4. Ingredion (INGR) upgraded to Neutral from Sell at Citi with analyst David Driscoll saying the worst is now likely behind the company's North American operations, which should resume growth in 2019 "when many of the transitory 2018 issues will be in the rear view mirror." 5. VeriSign (VRSN) upgraded to Neutral from Underweight at JPMorgan and to Outperform from Neutral at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SPXC SPX Corporation
$29.03

-0.22 (-0.75%)

01/23/18
UBSW
01/23/18
INITIATION
Target $41
UBSW
Buy
SPX Corporation initiated with a Buy at UBS
UBS analyst Damian Karas initiated SPX Corporation with a Buy rating and $41 price target.
09/18/18
BUCK
09/18/18
INITIATION
Target $41
BUCK
Buy
SPX Corporation initiated with a Buy at Buckingham
Buckingham analyst Robert Barry initiated SPX Corporation with a Buy and $41 price target saying EBITDA growth will be driven by an improving organic top line, new products and supportive key end markets.
WTS Watts Water
$70.10

-0.52 (-0.74%)

02/14/18
JANY
02/14/18
UPGRADE
JANY
Buy
Watts Water upgraded to Buy from Neutral at Janney Capital
02/14/18
02/14/18
UPGRADE
Target $83

Buy
Watts Water upgraded to Buy on lower taxes, higher multiple at Janney Capital
As previously reported, Janney Capital analyst Michael Gaugler upgraded Watts Water to Buy from Neutral after he raised his 2018 and 2019 estimates based on lowered income tax assumptions and raised his P/E multiple for the stock to 21x from 20x. Gaugler increased his fair value estimate on Watts shares to $83 from $69.
03/21/18
BOSC
03/21/18
DOWNGRADE
BOSC
Neutral
Watts Water downgraded to Neutral from Outperform at Boenning & Scattergood
Boenning & Scattergood downgraded Watts Water to Neutral from Outperform citing valuation.
12/04/18
GHSC
12/04/18
UPGRADE
Target $90
GHSC
Buy
Watts Water upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Walt Liptak upgraded Watts Water to Buy from Neutral and raised its price target to $90 from $83. Liptak said the selloff in shares provides a buying opportunity ahead of 2019 market share gains and profitability driven by sector growth, new products, and European restructuring. The analyst expects Watts' new product strategy that has already resulted in an acceleration in the Americas organic sales growth rate to continue into 2019 and for price increases and internal profit improvement initiatives to support earnings.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Recommendations
Amazon.com analyst commentary  »

Amazon.com remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Hot Stocks
Crispr Therapeutics signs collaboration agreement with ProBioGen »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$164.13

3.78 (2.36%)

07:13
01/22/19
01/22
07:13
01/22/19
07:13
Initiation
Constellation Brands initiated  »

Constellation Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

HBM

Hudbay Minerals

$5.65

0.03 (0.53%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Crispr Therapeutics rating change  »

Citi downgrades Crispr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$1.92

-0.05 (-2.54%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

FB

Facebook

$150.01

1.77 (1.19%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Periodicals
VC says Facebook the most 'vulnerable' big tech firm, CNBC reports »

Facebook is the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Hot Stocks
Peoples Bancorp reports Q4 net interest margin 3.77% vs. 3.68% sequentially »

Compared to 3.63% for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

AXGN

AxoGen

$16.00

0.64 (4.17%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Hot Stocks
AxoGen appoints Eric Sandberg CCO »

AxoGen (AXGN) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Earnings
Peoples Bancorp reports Q4 EPS 71c, consensus 67c »

Earnings per diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CTSO

CytoSorbents

$7.66

0.04 (0.52%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Hot Stocks
CytoSorbents expands partnership with Fresenius Medical Care to Korea and Mexico »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$60.80

2.57 (4.41%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$10.76

-0.395 (-3.54%)

07:08
01/22/19
01/22
07:08
01/22/19
07:08
Upgrade
Dicerna rating change  »

Dicerna upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$123.97

1.03 (0.84%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Travelers reports Q4 return on equity 10.9% »

Reports Q4 core return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

, RHHBY

Roche

$0.00

(0.00%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Voyager Therapeutics names Robert Hesslein as general counsel »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 01

    Feb

  • 18

    Mar

CAPR

Capricor Therapeutics

$0.62

-0.007 (-1.11%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Capricor Therapeutics announces outcome of FDA meeting for CAP-1002 »

Capricor Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Breaking Hot Stocks news story on Aurinia Pharmaceuticals »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

REXR

Rexford Industrial

$32.00

0.225 (0.71%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Rexford Industrial acquires two industrial properties for $27.6M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$87.31

-0.29 (-0.33%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Medtronic announces new data shared on IN.PACT Admiral DCB »

Medtronic announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 18

    May

  • 28

    May

BG

Bunge

$52.95

0.745 (1.43%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Bunge says Lupo, Bachrach, Boilini won't stand for re-election to board »

As part of Bunge's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:05
01/22/19
01/22
07:05
01/22/19
07:05
Hot Stocks
Aurinia says VOS demonstrates statistically superior efficacy versus Restasis »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

07:05
01/22/19
01/22
07:05
01/22/19
07:05
General news
Global stock markets under pressure after gloomy IMF report. »

Global stock markets…

BG

Bunge

$52.95

0.745 (1.43%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Bunge sees FY18 total segment adjusted EBIT below previously disclosed range »

The company provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPGP

IPG Photonics

$132.54

3.37 (2.61%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
IPG Photonics to acquire Padtec SND »

IPG Photonics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$126.64

1.37 (1.09%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Centene subsidiary selected by Arizona's Department of Corrections »

Centene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.